Antibiotic Resistance Market
完整報告名稱與涵蓋範圍
Antibiotic Resistance Market Size, Share & Trends Analysis Report By Pathogen (E. coli, K. pneumoniae, P. aeruginosa, S. aureus, A. baumannii, S. pneumoniae, H. influenzae, C. difficile, E. faecium), By Disease, By Technology, Region And Segment Forecasts, 2025-2034
報告摘要
Industry analysis indicates the Antibiotic Resistance Market globally will develop at a 6.8% CAGR during 2025–2034.
Antibiotic Resistance encompasses antimicrobial chemicals that are used to treat bacterial infections. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Several factors contribute to this trajectory, including heightened appetite for next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
From a regional perspective, mature markets in North America and Europe continue to hold meaningful shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and escalating investment in the sector.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Antibiotic Resistance Market Snapshot
Chapter 4. Global Antibiotic Resistance Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers & Challenges
4.3. Trends
4.4. Porter's Five Forces Analysis
4.5. Impact of COVID 19 Analysis
4.6. Clinical Trial/Pipeline Analysis 2020
Chapter 5. Market Segmentation 1: By Pathogen Estimates & Trend Analysis
5.1. By Pathogen & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Pathogen:
5.2.1.E. coli
5.2.2.K. pneumoniae
5.2.3.P. aeruginosa
5.2.4.S. aureus
5.2.5.A. baumannii
5.2.6.S. pneumoniae
5.2.7.H. influenzae
5.2.8.C. difficile
5.2.9.E. faecium
5.2.10. Other Pathogen
Chapter 6. Market Segmentation 2: By Technology Estimates & Trend Analysis
6.1. By Technology & Market Share, 2020& 2028
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Technology:
6.2.1. Antibiotics
6.2.2. Phage
6.2.3. Pep/Lys
6.2.4. Antibodies
6.2.5. Vaccine
6.2.6. Other Technology
Chapter 7. Market Segmentation 2: By Disease Estimates & Trend Analysis
7.1. By Disease & Market Share, 2020& 2028
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Disease:
7.2.1. cUTI
7.2.1. CDI
7.2.1. ABSSSI
7.2.1. HABP
7.2.1. CABP
7.2.1. cIAI
7.2.1. BSI
Chapter 8. Antibiotic Resistance Market Segmentation 3: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts By Pathogen, 2021 to 2034
8.1.2. North America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021 to 2034
8.1.3. North America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021 to 2034
8.1.3.1. U.S.
8.1.3.2. Canada
8.2. Europe
8.2.1. Europe Antibiotic Resistance Market Revenue (US$ Million) By Pathogen, 2021 to 2034
8.2.2. Europe Antibiotic Resistance Market Revenue (US$ Million) By Technology, 2021 to 2034
8.2.3. Europe Antibiotic Resistance Market Revenue (US$ Million) by Country, 2021 to 2034
8.2.3.1. Germany
8.2.3.2. France
8.2.3.3. Italy
8.2.3.4. Spain
8.2.3.5. UK
8.2.3.6. Romania
8.2.3.8. Netherland
8.2.3.8. Belgium
8.2.3.9. Rest of Europe
8.3. Asia Pacific
8.3.1. Asia Pacific Antibiotic Resistance Market revenue (US$ Million) By Pathogen, 2021 to 2034
8.3.2. Asia Pacific Antibiotic Resistance Market revenue (US$ Million) By Technology, 2021 to 2034
8.3.3. Asia Pacific Antibiotic Resistance Market revenue (US$ Million) by Country, 2021 to 2034
8.3.3.1. China
8.3.3.2. India
8.3.3.3. Japan
8.3.3.4. Australia
8.3.3.5. Rest of Asia Pacific
8.4. Latin America
8.4.1. Latin America Antibiotic Resistance Market revenue (US$ Million) By Pathogen, (US$ Million)
8.4.2. Latin America Antibiotic Resistance Market revenue (US$ Million) By Technology, (US$ Million)
8.4.3. Latin America Antibiotic Resistance Market revenue (US$ Million) by Country, (US$ Million) 2021 to 2034
8.4.3.1. Brazil
8.4.3.2. Rest of Latin America
8.5. Middle East & Africa
8.5.1. Middle East & Africa Antibiotic Resistance Market revenue (US$ Million) By Pathogen, (US$ Million)
8.5.2. Middle East & Africa Antibiotic Resistance Market revenue (US$ Million) By Technology, (US$ Million)
8.5.3. Middle East & Africa Antibiotic Resistance Market revenue (US$ Million) by Country, (US$ Million) 2021 to 2034
8.5.3.1. GCC Countries
8.5.3.2. Rest of Middle East & Africa
Chapter 8. Competitive Landscape
9.1. Company Profiles
9.1.1. The Medicines Company
9.1.2. Melinta Therapeutics
9.1.3. Arsanis
9.1.4. Phage Technologies S.A
9.1.5. Westway Health
9.1.6. Tetraphase Pharmaceuticals
9.1.7. BioVersys GmbH
9.1.8. Nabriva Therapeutics.
9.1.9. Macrolide Pharmaceuticals
9.1.10. Nemesis Bioscience
9.1.11. C3J Therapeutics, Inc
9.1.12. EpiBiome
9.1.13. discuva
9.1.14. SmartPhage
9.1.15. AmpliPhi Biosciences
9.1.16. Pherecydes Pharma
9.1.18. Micreos
9.1.18. Procarta Biosystems
9.1.19. Lumavita
9.1.20. Madam Therapeutics
9.1.21. Priaxon
9.1.22. Biolytx Pharmaceuticals
9.1.23. AntibioTx
9.1.24. Xellia Pharmaceuticals
9.1.25. Paratek Pharmaceuticals
9.1.26. Synereca Pharmaceuticals
9.1.28. Allecra Therapeutics
9.1.28. Fixed Phage
9.1.29. Enanta Pharmaceuticals, Inc
9.1.30. Demuris
9.1.31. Prommune
9.1.32. Biosergen
9.1.33. Innovation Pharmaceuticals
9.1.34. Aviragen Therapeutics
9.1.35. Achillion Pharmaceuticals
9.1.36. ImmunNovative Developments, S.L.
9.1.38. Achaogen, Inc.
9.1.38. SelectX Pharmaceuticals, Inc.
9.1.39. TaiGen Biotechnology Co., Ltd
9.1.40. Theravance Biopharma
9.1.41. Abbvie
9.1.42. KYORIN Pharmaceutical Co., Ltd.
9.1.43. Iterum Therapeutics Limited
9.1.44. Forge Therapeutics
9.1.45. Alopexx Vaccine LLC
9.1.46. Integrated Biotherapeutics
9.1.48. Hennepin Life Sciences
9.1.48. Fedora Pharmaceuticals Inc
9.1.49. Contrafect Corporation
9.1.50. Basilea Pharmaceutica Ltd.
9.1.51. AiCuris
9.1.52. RedHill Biopharma
9.1.53. Redx Pharma Plc/ Redx Anti Infectives Ltd.
9.1.54. ABAC Therapeutics
9.1.55. Alaxia SAS
9.1.56. Antabio S.A.S
9.1.58. Auspherix Ltd
9.1.58. BioFilm Pharma
9.1.59. Centauri Therapeutics Ltd
9.1.60. Combioxin SA
9.1.61. Da Volterra
9.1.62. Debiopharm International SA
9.1.63. Deinobiotics/Deinove
9.1.64. Destiny Pharma plc
9.1.65. Eligo Bioscience
9.1.66. Helperby Therapeutics Ltd
9.1.68. Karveel Pharmaceuticals
9.1.68. MaaT Pharma
9.1.69. Motif BioSciences, Inc / Motif Bio PLC
9.1.70. Mutabilis SAS
9.1.71. Neem Biotech Ltd
9.1.72. Northern Antibiotics Oy (Ltd)
9.1.73. Nosopharm
9.1.74. NovaBiotics Ltd
9.1.75. Phico Therapeutics Ltd
9.1.76. Polyphor Ltd
9.1.78. QureTech Bio AB
9.1.78. SetLance Srl
9.1.79. Ultupharma AB
9.1.80. Vaxdyn
9.1.81. Vibiosphen
9.1.82. Bioaster
9.1.83. Vivexia
9.1.84. KBP Biosciences
9.1.85. Absynth Biologics
9.1.86. Spero Therapeutics
9.1.88. Merck
9.1.88. Symphogen
9.1.89. Warp Drive Bio
9.1.90. Johnson & Johnson (Janssen)
9.1.91. Pfizer
9.1.92. Allergan
9.1.93. Novartis
9.1.94. AstraZeneca
9.1.95. Cipla
9.1.96. DSM Sinochem Pharmaceuticals
9.1.98. Wockhardt Ltd.
9.1.98. VenatoRx Pharmaceuticals
9.1.99. MicuRx
9.1.100. Entasis Therapeutics
9.1.101. Merlion Pharmaceuticals
9.1.102. Aridis Pharmaceuticals Inc
9.1.103. Other Prominent Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們